CNR1

The Hippocampal Risk Variant — How a CNR1 Intronic SNP Shapes Cannabis Brain Vulnerability

Deep in intron 2 of the CNR1 gene — about 400 base pairs upstream from an
alternative exon 3 transcription start site | An alternative promoter within
intron 2 of CNR1 that drives production of a novel CB1 receptor transcript with
a different 5' untranslated region; this isoform shows regionally selective expression
across brain areas including the hippocampus and prefrontal cortex — sits rs2023239,
a T-to-C substitution that alters CB1 receptor isoform balance in ways that matter
most for cannabis users. The C allele (reported as "G" in papers using coding-strand
notation, because CNR1 is encoded on the minus strand of chromosome 6) is the minor
allele globally at roughly 17–21% frequency, and it is the allele consistently
associated with greater neurobiological sensitivity to cannabis.

CB1 is the most abundant G-protein-coupled receptor in the central nervous system.
When THC — the primary psychoactive compound in cannabis — binds CB1, it floods the
same signaling pathway activated by the brain's endogenous cannabinoids anandamide
and 2-AG, releasing dopamine in the
nucleus accumbens | The brain's primary reward hub; dopamine release here encodes
the rewarding value of experiences and substances, and repeated activation by THC
progressively recalibrates reward set-points toward dependence, suppressing
glutamate and GABA release across the cortex, amygdala, hippocampus, and cerebellum.
Genetic variation in CNR1 shapes how powerfully this cascade operates — and rs2023239
sits at a regulatory junction that influences which CB1 transcript variants the brain
produces and in what quantity.

The Mechanism

Rs2023239 lies adjacent to a secondary promoter in CNR1 intron 2 that initiates
transcription of a distinct CB1 receptor mRNA with an alternative 5' untranslated
region (5'UTR). This alternative transcript shows
regionally selective expression in brain | Not all CB1 transcripts are expressed
equally everywhere; this secondary-promoter isoform is particularly expressed in brain
regions with dense CB1 signaling, including the hippocampus, amygdala, and prefrontal
cortex — the exact circuits involved in memory, emotion, and reward.
The alternative 5'UTR differs from the canonical transcript in its regulatory binding
sequences, affecting mRNA stability, translation efficiency, and potentially
microRNA targeting.

Unlike rs806368 (CNR1's 3'UTR regulatory variant, which is a validated eQTL across
three brain regions) and rs1049353 (the exon-synonymous variant near an exon splice
enhancer), rs2023239 does not have a confirmed eQTL relationship yet established in
large brain expression databases. Its functional effect is inferred from its position
— near, but not within, the alternative exon 3 promoter element — and from the
convergence of multiple independent behavioral and neuroimaging phenotypes that it
predicts.

The Evidence

Hippocampal volume in cannabis users. The most striking finding for rs2023239 comes
from a structural MRI study by
Schacht, Hutchison, and Filbey (2012) | Schacht JP et al. Associations between
cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy
cannabis users. Neuropsychopharmacology, 2012.
The study compared 37 heavy daily cannabis users (average 6+ days/week) with 37
age- and sex-matched healthy controls, plus an expanded group of 94 total cannabis users.
After controlling for intracranial volume, tobacco use, age, gender, and education,
cannabis users overall showed significantly smaller bilateral hippocampi (left: 6.9%
reduction, p=0.002; right: 7.1% reduction, p=0.001) and smaller left amygdalae
(p=0.01) compared to controls.

When genotype was incorporated, the rs2023239 C allele emerged as a powerful moderator:
C allele carriers showed substantially smaller bilateral hippocampal volumes among
cannabis users compared to non-user controls (both p<0.001, Cohen's d=1.48–1.63 — large
effects). This gene-by-cannabis interaction was not explained by overall group differences;
it was specific to the C allele genotype group within cannabis users. This finding is
consistent with the hippocampus being the brain region most densely expressing the CB1
receptor variant isoform associated with this intronic promoter region.

This hippocampal finding is from a single case-control study (n=74 matched pairs)
and has not yet been independently replicated in a separate cohort. The effect sizes
are large enough to be meaningful, but independent replication is needed before treating
this as established rather than emerging.

Cannabis withdrawal and craving. A 5-day abstinence paradigm study by
Haughey et al. (2008) | Haughey HM et al. Marijuana withdrawal and craving: influence
of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes.
Addiction, 2008
enrolled 105 daily college-age cannabis users who abstained for 5 days while
undergoing repeated assessment of withdrawal symptoms and craving. The rs2023239
T/C genotype showed a significant abstinence-by-genotype interaction on withdrawal
severity (F=6.71, p=0.012): T/C carriers experienced substantially greater
post-abstinence withdrawal than T/T homozygotes. T/C carriers also showed a main
effect of elevated craving across all measurement timepoints (F=4.3, p=0.041),
indicating the C allele's effect on craving is not specific to the abstinence period
but reflects a baseline difference in reward circuit sensitivity.

Cannabis cue-elicited brain activation. A neuroimaging study by
Hutchison et al. (2010) | Hutchison KE et al. Individual and additive effects of
the CNR1 and FAAH genes on brain response to marijuana cues.
Neuropsychopharmacology, 2010
found that rs2023239 C/G allele carriers showed significantly greater activation in
the orbitofrontal cortex, inferior frontal gyrus, and anterior cingulate gyrus compared
to T/T (A/A) carriers when viewing cannabis-associated cues. These are the brain
regions encoding cue salience, habitual behavior, and craving — their heightened
reactivity in C allele carriers is consistent with both the withdrawal and craving
findings above and with the hippocampal volume data.

Nicotine dependence haplotype. Rs2023239 participates in a CNR1 haplotype with
established nicotine dependence associations. In two independent samples (VAND: 688
subjects; VAANX: 961 subjects),
Chen et al. (2008) | Chen X et al. Cannabinoid receptor 1 gene association with
nicotine dependence. Arch Gen Psychiatry, 2008
identified the haplotype rs2023239–rs12720071–rs806368(C) as significantly associated
with nicotine dependence diagnosis and Fagerström Test for Nicotine Dependence scores
(p<0.001 in VAND, p=0.009 in VAANX). These associations were female-specific across
both samples — male participants did not show the same haplotype signal. This
sex-specificity may reflect estrogen–endocannabinoid interactions that modulate
nicotine reward differently between sexes.

Nicotine reinforcement paradox. A 2021 laboratory study by
Forget et al. (2021) | Forget B et al. The CB1R rs2023239 receptor gene variant
significantly affects the reinforcing effects of nicotine, but not cue reactivity,
in human smokers. Neuropsychopharmacology, 2021
found a counterintuitive result: C allele carriers (n=39) showed significantly
lower nicotine reinforcement — measured by behavioral preference for
nicotine-containing cigarettes over denicotinized ones — compared to T/T carriers
(n=65). No genotype difference was found for nicotine cue reactivity. This is not
necessarily contradictory to the haplotype dependence finding: the reinforcement
experiment measures acute nicotine reward in a controlled laboratory context, while
dependence develops through different repeated-exposure mechanisms. The C allele may
reduce initial acute nicotine reward while still contributing (through haplotype
context) to the compulsive continuation patterns that define dependence.

Alcohol cue craving and dependence. A meta-analysis of CNR1 polymorphisms in
alcohol dependence (Gamaieddin et al. 2021 | Gamaieddin I et al. Associations of
CB1 cannabinoid receptor (CNR1) gene polymorphisms with risk for alcohol dependence.
Drug Alcohol Depend, 2021) found that
C allele carriers of rs2023239 showed elevated craving in response to alcohol-associated
cues, and a codominant model showed OR 1.33 (95% CI 1.13–1.56) for alcohol dependence
risk across pooled samples — though this finding was underpowered (78.7% power at
OR=1.5) and the aggregate sample was only 704 cases and 681 controls.

Practical Implications

The convergence of findings across hippocampal volume, withdrawal, craving, and cue
reactivity gives rs2023239 a coherent behavioral profile: the C allele is associated
with a more reactive endocannabinoid circuit that responds more intensely to cannabis
exposure and abstinence. This has clear implications for cannabis use decisions.

The hippocampal volume finding is the most striking: the hippocampus is the brain's
primary memory consolidation and spatial navigation hub, and it contains some of the
highest CB1 receptor density in the brain. Volume loss in this region with heavy
cannabis use — moderated by rs2023239 genotype — is associated with impaired episodic
memory, mood regulation, and contextual fear extinction. For C allele carriers, the
dose-response relationship between cannabis exposure and hippocampal structure
appears steeper.

The sex-specific nicotine finding is also practically relevant for female C allele
carriers who smoke: the nicotine dependence haplotype involving rs2023239 suggests
a genotype-specific vulnerability that is not apparent in males.

The distinction between rs2023239 and the rs806368-rs1049353 haplotype is important:
these variants tag different LD blocks and different functional elements in CNR1,
meaning their effects are at least partially independent. Carriers of risk alleles
at all three loci face compounding endocannabinoid system vulnerability rather than
redundant signals.

Interactions

Rs2023239 is in a separate LD block from rs806368 and rs1049353, which form the primary
3'UTR haplotype block in CNR1. In European populations, rs2023239 tags a second CNR1
haploblock with rs1535255 and rs6454674. The Chen 2008 nicotine study explicitly showed
that the nicotine dependence signal involves a three-marker haplotype spanning both
LD blocks (rs2023239–rs12720071–rs806368). A three-year longitudinal study of first-episode
psychosis by Bobes et al. 2015 found a triple interaction between rs1049353, rs1535255,
and rs2023239 predicting positive symptom trajectory — suggesting these variants
collectively modulate CNR1 expression regulation in ways relevant to psychosis
vulnerability in the context of cannabis use.

FAAH rs324420 — which controls anandamide breakdown and has been co-studied with
rs2023239 in both the cannabis cue and withdrawal paradigms — adds a complementary
layer: carriers of the FAAH rs324420 C allele (reduced FAAH activity → elevated
anandamide) and the CNR1 rs2023239 C allele may face simultaneous upregulation of
endocannabinoid tone through two distinct nodes of the same pathway.